Table 6 Items regarding CS5: Patient with non-functioning GEP-NET, non-susceptible to surgery or to loco-regional treatment, with Ki-67 > 10 %, ECOG ≤2, AND POSITIVE OCTREOSCAN®: Is SSA treatment initiated? [36, 59]
Previous rounda | Median (p25-p75) | Median range | Participants in median range n (%) | Result | |
|---|---|---|---|---|---|
41. The use of SSA in monotherapy in these patients is reasonable in patients with Ki-67 <20 %. | 50.8 %: 7–9 | 7 (7–8) | 7–9 | 48 (84.2) | C - A |
42. The use of SSA in monotherapy in these patients is reasonable in case of low tumor load (hepatic ≤25 % and no extra-hepatic disease). | 63.1 %: 7–9 | 8 (7–8) | 7–9 | 50 (87.7) | C - A |
43. The use of SSA in monotherapy in these patients is reasonable in case of NETs of gastrointestinal origin. | 52.3 %: 7–9 | 7 (7–8) | 7–9 | 49 (86) | C - A |
44. In case of important comorbidities, SSAs are an option in these patients. | 8 (7–9) | 7–9 | 56 (86.2) | C - A | |
45. In these patients with Ki-67 from 10 to 20 % and/or high tumor load (extra-hepatic and/or hepatic >25 %) and/or NET of pancreatic origin, treatment is usually initiated with chemotherapy. | 66.2 %: 7–9 | 7 (7–8) | 7–9 | 48 (84.2) | C - A |
46. In these patients with Ki-67 from 10 to 20 % and/or high tumor load (extra-hepatic and/or hepatic >25 %) and/or NET of pancreatic origin, treatment is usually initiated with molecular targeted drugs (with the possibility of combination with SSA). | 7 (6–8) | 7–9 | 45 (69.2) | C - A | |
47. If discrepancy exists between the degree of cellular proliferation and the octreoscan® results, it is recommended to perform 18FDG-PET-TAC to help making a therapeutic decision. | 53.8 %: 7–9 | 7 (7–8) | 7–9 | 46 (80.7) | C - A |
48. If discrepancy exists between the degree of cellular proliferation and the octreoscan® results, a re-biopsy of the growing lesions will be considered. | 64.4 %: 7–9 | 7 (7–8) | 7–9 | 53 (93) | C - A |